How digital health companies are capitalizing on the GLP-1 boom
More Videos
Published
2 years agoon
By
admin
Patent protection for Wegovy — Novo Nordisk’s blockbuster weight loss drug, which contains the second generation GLP-1 active ingredient and is at least twice as effective — is expected to expire by the decade’s end.
Michael Siluk | UCG | Getty Images
For Gray Beard, a kindergarten teacher in Charlotte, North Carolina, losing weight had become a grueling task. She’d tried five different programs in her life and never found lasting results.
Her luck started to change last year, when she saw a promotion on Instagram for the Ro Body Program, a new offering from online health startup Ro. The ad said eligible patients could get prescribed GLP-1s, the buzzy class of obesity treatments that’s turned into a booming business in recent years.
Beard, 47, had previously sought a GLP-1 prescription, but her doctor “wouldn’t even try” to get it approved, assuming her insurance company would reject coverage of the costly medication, she said. GLP-1s cost roughly $1,000 per month before insurance and other rebates.
Customers of Ro’s Body Program could get prescribed a GLP-1, such as Novo Nordisk ‘s weight loss drug Wegovy or diabetes treatment Ozempic, and meet monthly with a doctor. They also get access to an educational curriculum, 24/7 messaging, one-on-one coaching with nurses and assistance with navigating insurance complexities.
Beard was 210 pounds when she first started the program early last year. She’s since lost 40 pounds and serves as an ambassador for Ro. She pays $30 per month for the GLP-1 treatment, after insurance coverage, along with a $145 monthly fee for the program. And she has no plans to leave.
“I’m fine if I have to stay on it forever,” Beard told CNBC.
Ro, founded as Roman in 2017, is part of a growing crop of digital health companies aiming to capitalize on the soaring demand for GLP-1s by building programs and services for users on top of the medications. The opportunity could be massive. Goldman Sachs analysts expect 15 million U.S. adults to be on anti-obesity drugs by 2030, and predict the industry could reach $100 billion in annual revenue by that time.
In addition to Wegovy and Ozempic, the GLP-1 class includes Eli Lilly’s highly popular weight loss drug Zepbound and diabetes treatment Mounjaro. GLP-1s mimic a hormone produced in the gut to suppress a person’s appetite and regulate blood sugar.
Like Ro, other non-drugmakers, including Calibrate, Sesame, Omada Health, Noom, Hims & Hers and even telehealth industry veterans Teladoc Health and WeightWatchers, have rolled out offerings geared toward patients on GLP-1s, or have expanded their services to include the popular medications.
Meanwhile, investors are cheering them on.
Shares of Ro competitor Hims & Hers popped 28% on May 20 after the company said it’s now offering compounded GLP-1 injections in addition to its oral medication kits. CEO Andrew Dudum told CNBC the company is confident customers will be able to access a consistent supply of the injections.

Supply shortages are one of the big hurdles for companies in the market, as spiking demand has made it difficult for many patients to access the treatments. There’s also been a rise of counterfeit products, according to the World Health Organization, which said in January that the combination of shortages and the “increased circulation of falsified versions” is particularly problematic for patients with Type 2 diabetes who count on the medication for disease management.
That’s not slowing down industry executives like Ro founder Zachariah Reitano.
Ro didn’t start out as a company focused on weight loss. Reitano launched it to sell treatments online for erectile dysfunction before moving on to hair loss and other pathologies.
In 2020, Ro switched to obesity management and, after Wegovy was approved by the Food and Drug Adminstration the following year, Reitano said patient inquiries started pouring in by the “tens of thousands.”
Now, Ro is shoveling marketing dollars into its GLP-1 program — from digital ads, TV commercials and posters lining subway stations, to influencer campaigns featuring patients such as Beard.
Reitano told CNBC that GLP-1s are like a “jetpack for positive behavior change.” Patients tend to exercise more, eat healthier and see around a 30% reduction in calorie intake, he said.
“Once you get a little bit of momentum, once you lose a little bit of weight, you’re sleeping better, you have more energy, you can go to the gym, you can eat better and then that’s that positive flywheel,” Reitano said.
Ro has raised around $1 billion in funding to date, according to PitchBook. The company was valued at about $7 billion as of early 2022, though that was before a steep drop in tech stocks and collapse in the initial public offering market forced many startups to dramatically lower their valuations.
WeightWatchers joins the market
WeightWatchers has been in business for over 60 years and is the name in the U.S. perhaps most synonymous with weight loss programs.
In December, the company entered the GLP-1 market, with a behavioral-support program that’s available through its general membership subscription, starting at $23 per month. Members can participate whether they get a GLP-1 prescription through their primary care physician or through the new WeightWatchers Clinic, introduced alongside the behavioral program.
Because GLP-1s suppress appetites, WeightWatchers quickly learned that it needed an entirely new program for people taking the meds, said Gary Foster, the company’s chief scientific officer.
“They don’t need help with what to do for dessert or how to deal with the bread on the table at a restaurant,” Foster said in an interview. “That’s like 50-60% of what we would do for people without meds.”
Clinic members who participate in the GLP-1 program have to pay an additional fee — starting at $99 a month — for exclusive access to registered dieticians, fitness professionals and care team coordinators.
WeightWatchers said in its first-quarter results earlier this month that 87,000 people had subscribed to the clinic, although not all of them are taking GLP-1s. The company expects to have between 140,000 and 160,000 clinic subscribers by year-end, the report said.
It hasn’t been enough to change WeightWatchers’ trajectory. The stock has plummeted 83% this year on concerns about the company’s debt load, its core weight loss business and Oprah Winfrey’s announced departure from the board in February.
With respect to GLP-1s and their impact on weight loss, “the landscape is quite exciting,” Foster said. “I think we should all celebrate and really be delighted by the fact that there are more tools in the toolbox to help people trying to manage their weight.”
Kim Gradwell with an Ozempic injection needle at her home in Dudley, North Tyneside, Britain, October 31, 2023.
Lee Smith | Reuters
Jennifer VanGilder, a 51-year-old economics professor at Ursinus College in Collegeville, Pennsylvania, said she’d tried countless methods to lose weight, from strict diets to services like the defunct Jenny Craig. She was considering bariatric surgery before she came across a program from digital health startup Calibrate.
Calibrate, founded in 2019, was one of the first companies to treat obesity by combining GLP-1s with one-on-one coaching. The program costs $199 a month, which doesn’t include the medication, and requires an initial three-month-long commitment.
VanGilder signed up nearly four years ago and started taking the weekly diabetes injection Ozempic specifically for weight loss. She later switched to Wegovy.
VanGilder said GLP-1s aren’t a miracle drug, but by taking them and putting in the work, she said she lost around 100 pounds of her 242-pound weight. The big difference between Calibrate and prior weight loss efforts, VanGilder said, is that she doesn’t feel like she’s dieting.
“That’s why I’ve been able to stay on it for as long as I have,” VanGilder said.
Calibrate is one of the only companies to regularly release reports detailing the results of its weight loss program. The company’s 2024 report examined data from roughly 16,000 members who completed at least one year of the program as of October, along with a smaller group of patients who continued for longer.
Average weight loss among patients was 16.2% at 12 months in the program, 17.3% at 18 months and 17.9% at 24 months, according to the report.
“Our data of proven outcomes shows that we can deliver faster, better results than some of the leading GLP-1 clinical trials,” said Dr. Kristin Baier, Calibrate’s vice president of clinical development, in an interview.
But Calibrate has hit some major speed bumps in the past couple years.
After raising $100 million in venture funding during the peak of the tech market in 2021, the combination of supply shortages, insurance challenges and the broader market swoon forced the startup to lay off hundreds of employees between 2022 and 2023. The company was acquired in October at a discount by private equity firm Madryn Asset Management.
Calibrate CEO Rob MacNaughton said the sector was “ill equipped” to manage the “dramatic demand that led to, at some point, severely, severely constrained supply” of GLP-1s last year.
Under new ownership, the company continues to promote its GLP-1 service, which its said is important because the drugs themselves aren’t sufficient.
“GLP-1 medications, while they are safe and effective, they are a tool,” said Baier. “They are not the entire treatment.”
Options for patients
Ro’s Reitano said shortages of Wegovy and other GLP-1s last year prompted his company to temporarily pause advertising. Ro also dolled out refunds and credits to patients in its program who weren’t able to pick up their medication within 30 days of receiving a prescription, he said.
Reitano said Ro has built up “both technical tools and operations” to help patients navigate supply issues. That includes transferring prescriptions to different pharmacies based on their GLP-1 supply and proximity to a patient. From July to August, the company made 50,000 phone calls to pharmacies across the U.S. to coordinate those transfers, Reitano said.
Ro has also expanded its medication offerings, adding Zepbound following its U.S. approval in November.
“We added that to our formulary, and that’s really when we started advertising again because we had confidence that we’d be able to get patients an option,” Reitano said.

Insurance problems persist, though.
Some employers have dropped weight loss drugs from their plans due to the costs associated with covering the treatments for thousands of patients. The federal Medicare program by law can’t cover weight loss drugs unless the prescription is for another approved health benefit, such as diabetes or cardiovascular health.
Eli Lilly and Novo Nordisk offer commercial savings card programs that aim to expand access to their GLP-1s. Eli Lilly allows people with insurance coverage for Zepbound to pay as low as $25 for a monthly prescription. And users who can’t get insurance coverage, may be able to get the drug for as low as $550 a month.
The high costs and difficult access led Hims & Hers to initially stay out of the GLP-1 market even after launching its new weight loss program in December
Dr. Craig Primack, senior vice president of weight management at Hims, said the company decided to offer treatment regimens based on drugs that had been studied and prescribed for decades.
“We’re going to have people, for one reason or another, who either don’t want an injection at this point, or are just looking for a different alternative,” Primack told CNBC in an interview in March. “These are tools we’ve been using in our field for a long, long time.”
Last week, Hims said customers can now access compounded GLP-1 medications via a prescription from a licensed health-care provider on the platform. Hims said it plans to make branded GLP-1 medications available to its customers once supply is consistently available. The company’s oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month.
Dudum said the company has partnered with one of the largest generic manufacturers in the U.S. and has a certain degree of exclusivity with the facility. The manufacturer has FDA oversight, he said.
Even before Hims introduced compounded GLP-1 injections to its weight loss offering, the company said it expects the program will generate more than $100 million in revenue by the end of 2025.
Beard, the Ro customer, has had to make some changes since starting the Body Program. She initially took Wegovy with no out-of-pocket costs, thanks to her insurance coverage and a savings card program from Novo Nordisk. But she hit a plateau on the drug, so she switched to Zepbound.
While there have been some hiccups along the way, Beard says the program has largely been a “seamless” addition to her day-to-day life, and that she no longer thinks about food all the time. She even got a family member to enroll.
“We’re not having any bad side effects, so why go off of it?” she said, adding “it’s helped both of us get to the weight we want.”
Don’t miss these exclusives from CNBC PRO

You may like
Technology
From Llamas to Avocados: Meta’s shifting AI strategy is causing internal confusion
Published
5 hours agoon
December 9, 2025By
admin

Meta CEO Mark Zuckerberg makes a keynote speech at the Meta Connect annual event at the company’s headquarters in Menlo Park, Calif., on Sept. 25, 2024.
Manuel Orbegozo | Reuters
Meta CEO Mark Zuckerberg was so optimistic last year about his company’s Llama family of artificial intelligence models that he predicted they would become the “most advanced in the industry” and “bring the benefits of AI to everyone.”
But after including a whole section on Llama in his opening remarks during Meta’s earnings call in January of this year, he mentioned the brand name only once on the latest call in October. The company’s obsession with its open-source large language model has given way to a very different approach to AI, one focused around a multibillion-dollar hiring spree to bring in top industry talent that could help Meta take on the likes of OpenAI, Google and Anthropic.
As 2025 comes to a close, Meta’s strategy remains scattershot, according to insiders and industry experts, feeding the perception that the company has fallen further behind its top AI rivals, whose models are rapidly gaining adoption in the consumer and enterprise markets.
Meta is pursuing a new Llama successor and frontier AI model, codenamed Avocado, CNBC has learned. People with knowledge of the matter said many within the company were expecting the model to be released before the end of this year, but that the plan now is for that to happen in the first quarter of 2026. The model is wrestling with various training-related performance testing intended to ensure the system is well received when it eventually debuts, said the people, who asked not to be named because they weren’t authorized to speak on the matter.
“Our model training efforts are going according to plan and have had no meaningful timing changes,” a Meta spokesperson said in a statement.
With its stock underperforming the broader tech sector this year and badly trailing Google parent Alphabet, Wall Street is looking for a sense of direction and a path to a return on investment after Meta spent $14.3 billion in June to hire Scale AI founder Alexandr Wang and a handful of his top engineers and researchers. Four months after that announcement, which included Meta purchasing a big stake in Scale, the social media company raised its 2025 guidance for capital expenditures to between $70 billion and $72 billion from a prior range of $66 billion to $72 billion.
“In many ways, Meta has been the opposite of Alphabet, where it entered the year as an AI winner and now faces more questions around investment levels and ROI,” analysts at KeyBanc Capital Markets wrote in a November note to clients. The firm recommends buying both stocks.

At the heart of Meta’s challenge is the sustained dominance of its core business: digital advertising.
Even with annual sales in excess of $160 billion, Meta’s ad targeting business, driven by massive improvements in AI and the popularity of Instagram, is growing revenue north of 20% a year. Investors have lauded the company for using AI to bolster the strength of its cash cow and to make the organization more efficient and less bloated.
But Zuckerberg has much grander ambitions, and the new guard he’s brought in to push the future vision of AI has no background in online ads. The 41-year-old founder, with a net worth of more than $230 billion, has suggested that if Meta doesn’t take big swings, it risks becoming an afterthought in a world that’s poised to be defined by AI.
Until recently, Meta’s unique position in AI was the open-source nature of its Llama models. Unlike other AI models, Meta’s technology was made freely available so third-party researchers and others could access the tools and ultimately improve them.
“Today, several tech companies are developing leading closed models,” Zuckerberg wrote in a blog post in July 2024. “But open source is quickly closing the gap.”
He’s since started changing his tune. Zuckerberg hinted over the summer that Meta was considering shaking up its approach to open source after the April release of Llama 4, which failed to captivate developers. Zuckerberg said in July that, “We’ll need to be rigorous about mitigating these risks and careful about what we choose to open source.”
Avocado, when it’s eventually made available, could be a proprietary model, according to people familiar with the matter. That means outside developers wouldn’t be able to freely download its so-called weights and related software components.
Some at Meta were upset that the R1 model released by Chinese AI lab DeepSeek earlier this year incorporated pieces of Llama’s architecture, the people said, further underscoring the risks of open source and hammering home the idea that the company should overhaul its strategy.
The company’s high-priced AI hires and leaders of the recently launched Meta Superintelligence Labs, or MSL, have also questioned the open-source AI strategy and favored creating a more powerful proprietary AI model, CNBC reported in July. A Meta spokesperson said at the time that the company’s “position on open source AI is unchanged.”
The Llama 4 flub was a significant catalyst in Zuckerberg’s pivot, the people said, and also led to a major internal shake-up. Chris Cox, Meta’s chief product officer and a 20-year company veteran who was hired as its 13th software engineer, no longer oversees the AI division, formally known as the GenAI unit, after the botched release, the people said.
Zuckerberg went on a spending spree to retool Meta’s AI leadership.
He landed on Wang, then Scale AI’s 28-year-old CEO, who was named Meta’s new chief AI officer and, in August, became the head of an elite unit called TBD Lab. Avocado is being developed inside TBD, people familiar with the matter said.
Alexandr Wang, CEO of ScaleAI speaks on CNBC’s Squawk Box outside the World Economic Forum in Davos, Switzerland on Jan. 23, 2025.
Gerry Miller | CNBC
OpenAI CEO Sam Altman said in June that Meta was trying to lure talent from his company with gigantic pay packages, including sky-high $100 million signing bonuses, which Meta said at the time was a misrepresentation.
Along with Wang came other tech bigwigs, including former GitHub CEO Nat Friedman, who heads the product and applied research arm of MSL, and Shengjia Zhao, who was a ChatGPT co-creator. They’ve brought with them modern methods that have become the standard for frontier AI development in Silicon Valley, and have upended the traditional software development process inside Meta, the people said.
Meta’s AI culture shift
Wang is now under pressure to deliver a top-tier AI model that helps the company regain momentum against rivals like OpenAI, Anthropic and Google, the people said.
That pressure has only increased as competitors stepped up their game. Google’s Gemini 3, unveiled last month, has drawn solid reviews from users and analysts. OpenAI recently announced new updates to its GPT-5 AI model, while Anthropic debuted its Claude Opus 4.5 model in November shortly after releasing two other major models.
Analysts previously told CNBC that there’s no clear leading AI model, because some perform better on certain tasks like conversations or coding. But the one constant is that all of the major model creators have to spend a lot of money on AI to maintain any competitive edge, they said.
A hefty dose of that spending lines the pockets of Nvidia, the leading developer of AI graphics processing units. Nvidia CEO Jensen Huang laid out the state of play during his company’s earnings call in November, after the chipmaker reported 62% year-over-year revenue growth. He highlighted a number of model developers as big customers, including Elon Musk’s xAI.
“We run OpenAI. We run Anthropic. We run xAI because of our deep partnership with Elon and xAI,” Huang said. “We run Gemini. We run Thinking Machines. Let’s see, what else do we run? We run them all.”
At no point did Huang reference Llama, although elsewhere on the call he said Meta’s Gem, “a foundation model for ad recommendations trained on large-scale GPU clusters,” drove an improvement in ad conversions at Meta in the second quarter.
Wang isn’t the only Meta exec feeling the heat.
Friedman has also been tasked with producing a breakout AI product, the people said. He was responsible for Meta’s September launch of Vibes, a feed of AI-generated short videos, which is widely viewed as inferior to OpenAI’s Sora 2, they said. Former employees and creators told CNBC that the product was rushed to market and lacked key features, like the ability to generate realistic lip-synched audio.
Although Vibes has attracted more interest to the company’s stand-alone Meta AI app, it trails the Sora app as measured by downloads, according to data provided to CNBC by Appfigures.
Pressure is being felt across Meta’s AI organizations, where 70-hour workweeks have become the norm, the people said, while teams have also been hit with layoffs and restructurings throughout the year.
In October, Meta cut 600 jobs in MSL to reduce layers and operate more quickly. Those layoffs impacted employees in areas like the Fundamental Artificial Intelligence Research unit, or FAIR, and played a key role in chief AI scientist Yann LeCun’s decision to leave the company to launch a startup, according to people with knowledge of the matter.
LeCun declined to comment.
Yann LeCun, Meta’s former chief AI scientist, says people move on.
Getty Images
Zuckerberg’s high-stakes decision to turn to outsiders like Wang and Friedman to lead the company’s AI efforts represented a major change for a company that’s historically promoted long-tenured workers to top posts, the people said.
In Wang and Friedman, Zuckerberg has handed the controls to experts in infrastructure and related systems, rather than consumer apps. The new leaders also brought a different management style and one that’s unfamiliar inside Meta.
In particular, insiders told CNBC that Wang and Friedman are more cloistered in their communications, a contrast to a historically open approach of sharing work and chatting on the company’s Workplace internal social network
Members of Wang’s TBD Lab, who work near Zuckerberg’s office, don’t use Workplace, people familiar said, adding that they’re not even on the network and that the group operates like a separate startup.
However, Zuckerberg isn’t giving the new AI leadership team complete autonomy. Aparna Ramani, engineering vice president, who has been with Meta for nearly a decade, has been put in charge of overseeing the distribution of computing resources for MSL, the people said.
And in October, Vishal Shah was moved from leading the company’s metaverse initiatives within Reality Labs, where he’d been for four years, to a new role as vice president of AI Products, working with Friedman. Shah is considered a loyal lieutenant who has helped act as a bridge between the company’s traditional social apps like Instagram and newer projects like Reality Labs, the people said.
Meta confirmed last week that it plans to cut resources to its virtual reality and related metaverse initiatives, shifting its attention to its popular AI-infused glasses developed with EssilorLuxottica.
‘Demo, don’t memo’
One of the biggest points of tension between the old and the new is in the realm of software development, people familiar with the matter said.
In creating products, Meta has traditionally sought input from numerous groups responsible for areas like front-end user interface, design, algorithmic feeds and privacy, the people said. The multistep process was intended to ensure some level of uniformity among the company’s apps that attract billions of users each day.
But the many internal tools built over the years to help coders create software and features weren’t developed to accommodate foundation models. Meta’s new AI leaders, notably Friedman, view them as bottlenecks slowing down what should be a rapid-fire development process, the people said.
Friedman has called for MSL to use newer tools that have been calibrated to incorporate multiple AI models and various kinds of coding automation software often called AI agents, the people said.
“They have this mantra now saying ‘Demo, don’t memo,'” Lovable CEO Anton Osika said in October at the Masters of Scale Summit in San Francisco, about Meta’s new development process.
Osika said Meta employees have been using Lovable’s tools to more quickly build internal apps, specifically referencing the company’s finance teams, which have turned to Lovable to create software for tracking head count and planning.
An illustration photo shows the event of Meta launching the Vibes platform, Suqian City, Jiangsu Province, China on September 26, 2025.
Cfoto | Future Publishing | Getty Images
While Meta continues retooling its app development methods and pushes toward releasing Avocado, the company has been experimenting with other AI models on its products. Vibes, for instance, relied on AI models from Black Forest Labs and Midjourney, a startup that counts Friedman as an advisor.
Meta is also altering its approach to infrastructure, and is increasingly turning to third-party cloud computing services like CoreWeave and Oracle for developing and testing AI features as it builds out its own massive data centers, the people said.
The social media giant announced in October that it signed a joint venture agreement with Blue Owl Capital as part of a $27 billion deal to help fund and develop the gargantuan Hyperion data center in Richland Parish, Louisiana. The company said at the time that the partnership provides the “the speed and flexibility” Meta needs to build the data center and support its “long-term AI ambitions.”
Despite the company’s challenges in 2025, Zuckerberg’s message to employees and investors is that he’s more committed than ever to winning. At the top of the company’s earnings call in October, Zuckerberg said MSL is “off to a strong start.”
“I think that we’ve already built the lab with the highest talent density in the industry,” Zuckerberg said. “We’re heads down developing our next generation of models and products and I’m looking forward to sharing more on that front over the coming months.”

Technology
Paramount’s hostile Warner Bros. bid, Meta’s AI course correction, McDonald’s value crackdown and more in Morning Squawk
Published
5 hours agoon
December 9, 2025By
admin

David Ellison, chairman and chief executive officer of Paramount Skydance Corp., center, outside the New York Stock Exchange (NYSE) in New York, US, on Monday, Dec. 8, 2025.
Michael Nagle | Bloomberg | Getty Images
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Here are five key things investors need to know to start the trading day:
1. One battle after another
Paramount Skydance CEO David Ellison isn’t taking his loss to Netflix in the bidding war for Warner Bros. on the chin. Paramount announced yesterday that it’s going directly to WBD shareholders with a $30 per share, all-cash hostile bid, with Ellison telling CNBC that he wants “to finish what we started.”
Here’s what to know:
- Paramount’s offer is the same one that Warner Bros. Discovery executives passed over in favor of Netflix’s last week. But this time, the decision will rest in the hands of WBD stakeholders.
- President Donald Trump over the weekend said the Netflix-WBD deal “could be a problem,” citing the streamer’s potential market share should the deal go through. Trump also said he’d “be involved” in the approval process.
- Paramount’s hostile bid is backed by Jared Kushner — Trump’s son-in-law — according to a regulatory filling.
- Meanwhile, Comcast President Mike Cavanagh said he believed his company’s proposal was “light” on cash compared to the other two bids.
- Paramount shares surged 9% in yesterday’s session while shares of Warner Bros. Discovery jumped more than 4%. Netflix shares pulled back by more than 3%.
- Follow live market updates here.
Disclosure: Comcast is the parent company of NBCUniversal, which owns CNBC. Versant would become the new parent company of CNBC upon Comcast’s planned spinoff of Versant.
2. DC’s AI moves
Nvidia H200 chips in an eight-GPU Nvidia HGX system.
Nvidia
Trump announced yesterday that Nvidia will be allowed to ship its H200 artificial intelligence chips to “approved customers” in China and other countries. The caveat: Only if the U.S. gets a 25% cut.
The Department of Commerce is finalizing the details, Trump said in a social media post, adding that “the same approach will apply to AMD, Intel” and other U.S. firms. Shares of Nvidia, AMD and Intel all rose in overnight trading. Trump also said that Chinese President Xi Jinping “responded positively” to the plan.
Meanwhile, House Democrats are creating a commission on AI, hoping to position themselves as leaders on the issue. As CNBC’s Emily Wilkins notes, the move comes as the tech industry ramps up its presence in D.C. and its campaign spending.
3. From Llamas to Avocados
Meta CEO Mark Zuckerberg makes a keynote speech during the Meta Connect annual event, at the company’s headquarters in Menlo Park, California, on Sept. 25, 2024.
Manuel Orbegozo | Reuters
Meta has poured billions of dollars into overhauling its AI strategy. But as CNBC’s Jonathan Vanian reports, the shift has led to internal confusion and a haphazard strategy.
CEO Mark Zuckerberg began the year by touting Meta’s Llama family of AI models, which he said would become the “most advanced in the industry.” But CNBC has learned that Meta is now focused on a new AI model codenamed Avocado that could be proprietary instead of open source.
Elsewhere in Big Tech, Apple has seen significant churn among its top brass in recent days, including the departures of its head of AI and its top lawyer. The iPhone maker’s chip leader, Johny Srouji, reassured staff in a memo yesterday that he isn’t planning to leave “anytime soon,” following a report that he was considering departing.
Get Morning Squawk directly in your inbox
4. Farm aid
Dan Duffy uses a tractor to plant soybeans on land he farms with his brother on April 28, 2025 near Dwight, Illinois.
Scott Olson | Getty Images
Trump announced a $12 billion aid package for farmers impacted by tariffs yesterday, saying the funds would come from revenues generated by the tariffs.
A White House official told CNBC that up to $11 billion of that sum will go to the Agriculture Department’s new Farmer Bridge Assistance program to distribute one-time payments to row crop farmers. The other $1 billion will be held as the department evaluates the market, the official said.
Trump, meanwhile, suffered a blow in court yesterday. A federal judge overturned his ban on new wind power projects, saying it was “arbitrary and capricious and contrary to law.”
5. McDonald’s New Year’s resolution
A customer waits to order food at a McDonalds fast food restaurant on July 26, 2022 in Miami, Florida.
Joe Raedle | Getty Images
McDonald’s is putting its franchisees under a more intense microscope in 2026. The fast-food titan said it will look at how their prices align with value goals as McDonald’s aims to woo more price-conscious consumers, according to a memo viewed by CNBC.
McDonald’s will update its standards for franchisees — who run about 95% of McDonald’s restaurants — and “holistically assess” their pricing, the memo shows. If franchise owners do not comply with the new standards, they could face penalties such as being barred from opening additional stores or having their agreements with the company terminated.
The Daily Dividend
IBM CEO Arvind Krishna joined CNBC’s “Squawk on the Street” yesterday to discuss the company’s acquisition of data streaming platform Confluent in an $11 billion deal. Confluent shares soared 29% following the announcement.

— CNBC’s Alex Sherman, David Faber, Lillian Rizzo, Sean Conlon, Emily Wilkins, Dan Mangan, Kevin Breuninger, Jonathan Vanian, Kif Leswing, Chris Eudaily, Steve Kovach, Spencer Kimball and Amelia Lucas contributed to this report. Josephine Rozzelle edited this edition.
Technology
SF mayor’s downtown revival project has reeled in $60 million from Google, OpenAI and others
Published
5 hours agoon
December 9, 2025By
admin

San Francisco Mayor Daniel Lurie speaks during a press conference at San Francisco City Hall on Oct. 23, 2025 in San Francisco, California.
Justin Sullivan | Getty Images
San Francisco’s Downtown Development Corporation, launched in April by Mayor Daniel Lurie, said on Tuesday that it’s received over $60 million in early commitments from donors including Google and OpenAI to help revive the city’s center.
“I think people view this as a generational moment,” Shola Olatoye, CEO of the SFDDC, told CNBC in an interview. “San Francisco has captured the world’s, and the country’s, imagination as a global hub of innovation and industry. The folks who want to build businesses, raise their families here, and visit, recognize the important work that is underway and want to see it continue.”
In October, Lurie said the group, a nonprofit public benefit corporation, had raised $50 million for its efforts, up from $40 million at the time of its debut. When campaigning for mayor last year, Lurie touted his ability to fundraise, drawing on his past experience at the anti-poverty nonprofit Tipping Point Community, laying the groundwork for public-private partnerships to help revitalize San Francisco.
In addition to Google and OpenAI, SFDDC has raised money from backers including Visa, Thoma Bravo, Ripple, Salesforce, Amazon, Emerson Collective, Sixth Street and Gap. The funds will help support Lurie’s Heart of the City initiative, which prioritizes street safety and cleanliness, small business support and more.

Olatoye said some of the funding will also be deployed to fill vacant spaces in key retail spots such as along Powell and Stockton streets.
“We’re going to provide direct grants to these businesses to provide business support, marketing support and legal support,” Olatoye said. “And then actual below market capital from some of our lending partners to go in and actually fix up these spaces and get those businesses in there, get people spending money and generating economic activity for the city of San Francisco.”
Money will also be dedicated to a new Embarcadero Park, inspired by New York City’s Bryant Park. Lurie has often cited Michael Bloomberg’s efforts as mayor of New York as inspiration for his work, and the DDC is drawing on models used in New York as well as Detroit.
While a number of metrics show that San Francisco has bounced back dramatically from its pandemic lull, the city has a lot of work to do to prepare for an active 2026. Super Bowl LX is coming to the area in February, along with the Pro Bowl Games. In the summer, people will pack into the Bay Area for some of the FIFA World Cup.
“When downtown thrives, our residents, families and small business owners all benefit,” Lurie said in a statement. “By strengthening public safety, cutting red tape and leaning into our arts and culture, we are bringing people back to our streets.”
The first-term mayor notched a significant political win in October as President Donald Trump reversed his decision to deploy the National Guard in downtown San Francisco, saying Lurie was making “substantial progress” on crime in the city. Trump also said he was swayed by Nvidia CEO Jensen Huang and Salesforce CEO Marc Benioff.
The city has been boosted over the last year by a surge in investment and activity related to artificial intelligence. CBRE data on venture funding show 2025 is expected to surpass the record reached in 2021, thanks in large part to AI investments in San Francisco and Silicon Valley.
In addition, crime rates are down 30% from 2024, with event bookings and tourism on the rise, and residential and commercial real estate heating up.
“There’s no doubt that there is a lot of attention on us and we are super focused on outcomes and using data to ensure we can hold ourselves accountable,” Olatoye said.

Trending
-
Sports2 years agoStory injured on diving stop, exits Red Sox game
-
Sports3 years ago‘Storybook stuff’: Inside the night Bryce Harper sent the Phillies to the World Series
-
Sports2 years agoGame 1 of WS least-watched in recorded history
-
Sports3 years agoButton battles heat exhaustion in NASCAR debut
-
Sports3 years agoMLB Rank 2023: Ranking baseball’s top 100 players
-
Sports4 years ago
Team Europe easily wins 4th straight Laver Cup
-
Environment3 years agoJapan and South Korea have a lot at stake in a free and open South China Sea
-
Environment1 year agoHere are the best electric bikes you can buy at every price level in October 2024
